🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Metropolis Healthcare Limited METROPOLIS NSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.metropolisindia.com
Company Profile ↓
₹563.40
+14.58% 1Y
Mkt Cap₹11,680.85 Cr
P/E61.31
P/B7.72
Div. Yield0.35%
52W High₹573.55
52W Low₹420.92
Book Value₹72.98
EPS (TTM)₹9.19

Company Overview

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 15.7%.

Steady Revenue Expansion

Revenue has grown at a 12.8% CAGR over the past five years.

Healthy Margins

Operating margin of 16.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,645.85 Cr (+23.6% YoY); net profit ₹190.02 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +23.6%, earnings +31.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 12.8%, profit CAGR 10.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:12.75%
1 Year:23.64%

Compounded Profit Growth

5 Years:9.97%
1 Year:31.08%

Stock Price Performance

1 Year:+14.58%
6 Months:+17.58%
3 Months:+19.54%
1 Month:+7.13%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 93% of range
₹420.92 ₹573.55
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)57.20 · Neutral
Price Performance
1M+7.13%
3M+19.54%
6M+17.58%
1Y+14.58%
Valuation vs Sector

P/E of 61.31 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 12.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 61.3.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
61.31
Industry PE
39.97
Forward P/E
37.10
PEG Ratio
-
Book Value
₹72.98
Price to Book
7.72
P/S
7.11
EV/EBITDA
29.25
Dividend Yield
0.35%

Growth (CAGR)

Revenue 5Y
12.75%
Profit 5Y
9.97%
Revenue (YoY)
23.64%
Earnings (YoY)
31.08%

Profitability & Returns

ROCE
15.73%
ROE
12.56%
ROA
8.89%
Profit Margin
11.55%
Op Margin
16.23%
Gross Margin
78.88%
EPS (Latest Qtr)
₹2.46
EPS (TTM)
₹9.19

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
1.27
Current Ratio
1.40
Debt
₹231.91 Cr
Total Assets
₹2,138.05 Cr
Current Assets
₹468.61 Cr
Working Capital
₹134.59 Cr

Ownership

Promoter Holding
48.86%
Chg in Prom Hold
-0.01%
FII / Inst Holding
44.96%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹11,680.85 Cr
Total Revenue (TTM)
₹1,645.85 Cr
EBITDA
₹417.44 Cr
Free Cash Flow
₹299.51 Cr
Operating Cash Flow
₹350.70 Cr
Shares Outstanding
₹20.73 Cr
Gross Margin
78.88%
Payout Ratio
10.88%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 METROPOLIS Metropolis Healthcare Limited NSEPHARMA 563.40 61.31 ₹11,680.85 Cr 0.35% 15.73% 12.56% 12.75% 9.97%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 283.00 Cr277.00 Cr308.00 Cr291.00 Cr331.00 Cr313.00 Cr350.00 Cr322.77 Cr345.29 Cr386.06 Cr-405.91 Cr424.68 Cr
Cost of Revenue -------66.94 Cr73.59 Cr84.72 Cr-87.29 Cr82.79 Cr
Gross Profit -------255.82 Cr271.70 Cr301.34 Cr-318.62 Cr341.89 Cr
Operating Expenses 212.00 Cr214.00 Cr234.00 Cr226.00 Cr251.00 Cr235.00 Cr260.00 Cr211.51 Cr238.03 Cr242.43 Cr-255.65 Cr272.47 Cr
Operating Income 47.00 Cr42.00 Cr53.00 Cr40.00 Cr54.00 Cr53.00 Cr63.00 Cr44.31 Cr33.67 Cr58.91 Cr-62.97 Cr69.43 Cr
EBITDA 70.00 Cr63.00 Cr75.00 Cr65.00 Cr80.00 Cr79.00 Cr90.00 Cr74.56 Cr69.27 Cr97.27 Cr-94.77 Cr116.29 Cr
Interest Expense 6.00 Cr6.00 Cr6.00 Cr5.00 Cr6.00 Cr5.00 Cr5.00 Cr4.53 Cr4.60 Cr5.20 Cr-5.73 Cr7.93 Cr
Pretax Income 42.00 Cr39.00 Cr48.00 Cr37.00 Cr51.00 Cr51.00 Cr61.00 Cr42.34 Cr36.04 Cr61.23 Cr-57.16 Cr69.76 Cr
Tax Provision 8.40 Cr10.14 Cr12.48 Cr9.62 Cr14.28 Cr12.75 Cr14.64 Cr10.86 Cr6.81 Cr15.99 Cr-15.07 Cr18.80 Cr
Net Income 33.00 Cr29.00 Cr36.00 Cr27.00 Cr37.00 Cr38.00 Cr47.00 Cr31.36 Cr29.14 Cr45.06 Cr-41.39 Cr50.90 Cr
Diluted EPS 1.631.411.731.331.781.852.27-1.422.172.531.992.46

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 456.00 Cr475.00 Cr545.00 Cr647.00 Cr761.00 Cr856.00 Cr998.00 Cr-1,148.21 Cr1,207.71 Cr1,331.20 Cr1,645.85 Cr
Cost of Revenue --------263.69 Cr260.72 Cr278.88 Cr347.52 Cr
Gross Profit --------884.52 Cr946.99 Cr1,052.32 Cr1,298.32 Cr
Operating Expenses 339.00 Cr359.00 Cr405.00 Cr467.00 Cr559.00 Cr619.00 Cr708.00 Cr-675.70 Cr743.59 Cr858.00 Cr1,031.20 Cr
Operating Income 96.00 Cr99.00 Cr123.00 Cr162.00 Cr183.00 Cr198.00 Cr244.00 Cr-208.82 Cr203.40 Cr194.31 Cr267.12 Cr
EBITDA 117.00 Cr116.00 Cr140.00 Cr181.00 Cr203.00 Cr237.00 Cr290.00 Cr-303.52 Cr291.69 Cr318.11 Cr417.44 Cr
Interest Expense 2.00 Cr2.00 Cr2.00 Cr4.00 Cr4.00 Cr13.00 Cr12.00 Cr-26.80 Cr22.54 Cr18.57 Cr24.54 Cr
Pretax Income 101.00 Cr128.00 Cr160.00 Cr164.00 Cr187.00 Cr169.00 Cr244.00 Cr-187.50 Cr174.69 Cr190.85 Cr259.18 Cr
Tax Provision 33.33 Cr46.08 Cr52.80 Cr52.48 Cr63.58 Cr40.56 Cr61.00 Cr-44.11 Cr46.23 Cr45.34 Cr67.99 Cr
Net Income 68.00 Cr82.00 Cr107.00 Cr112.00 Cr124.00 Cr128.00 Cr183.00 Cr-142.88 Cr127.82 Cr144.97 Cr190.02 Cr
Diluted EPS 15.4420.1026.6127.295.996.298.95-6.956.227.049.19

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 462.00 Cr391.00 Cr512.00 Cr526.00 Cr550.00 Cr750.00 Cr1,000.00 Cr-1,501.61 Cr1,555.06 Cr1,867.34 Cr2,138.05 Cr
Current Assets --------302.73 Cr315.83 Cr345.94 Cr468.61 Cr
Cash & Equivalents --------68.83 Cr62.62 Cr39.48 Cr54.78 Cr
Inventory --------44.59 Cr38.69 Cr47.84 Cr45.49 Cr
Receivables --------121.89 Cr126.28 Cr147.95 Cr170.29 Cr
Total Liabilities --------510.90 Cr455.79 Cr532.70 Cr613.50 Cr
Current Liabilities --------264.97 Cr245.87 Cr294.33 Cr334.02 Cr
Long Term Debt --------28.61 Cr05.27 Cr0
Total Debt 14.00 Cr5.00 Cr1.00 Cr1.00 Cr18.00 Cr67.00 Cr112.00 Cr-266.38 Cr197.06 Cr204.13 Cr231.91 Cr
Total Equity 362.00 Cr279.00 Cr324.00 Cr415.00 Cr418.00 Cr523.00 Cr706.00 Cr-988.23 Cr1,096.16 Cr1,330.97 Cr1,513.16 Cr
Shares Outstanding --------20.48 Cr20.49 Cr20.72 Cr20.73 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 69.00 Cr91.00 Cr102.00 Cr104.00 Cr90.00 Cr215.00 Cr249.00 Cr-247.09 Cr264.07 Cr262.75 Cr350.70 Cr
Investing Cash Flow -56.00 Cr96.00 Cr-86.00 Cr1.00 Cr36.00 Cr-104.00 Cr63.00 Cr-46.79 Cr-89.41 Cr-201.06 Cr-223.13 Cr
Financing Cash Flow -9.00 Cr-174.00 Cr-17.00 Cr-87.00 Cr-118.00 Cr-55.00 Cr-33.00 Cr--292.33 Cr-181.20 Cr-86.63 Cr-115.29 Cr
Capital Expenditure -23.00 Cr-12.00 Cr-57.00 Cr-14.00 Cr-23.00 Cr-36.00 Cr-28.00 Cr--52.63 Cr-63.76 Cr-68.61 Cr-51.18 Cr
Free Cash Flow 46.00 Cr79.00 Cr45.00 Cr90.00 Cr67.00 Cr179.00 Cr221.00 Cr-194.46 Cr200.31 Cr194.13 Cr299.51 Cr
Net Change in Cash 4.00 Cr14.00 Cr-1.00 Cr18.00 Cr8.00 Cr56.00 Cr279.00 Cr-1.56 Cr-6.54 Cr-24.94 Cr12.28 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------77.0%78.4%79.1%78.9%
Operating Margin % 21.1%20.8%22.6%25.0%24.0%23.1%24.4%-18.2%16.8%14.6%16.2%
Net Margin % 14.9%17.3%19.6%17.3%16.3%15.0%18.3%-12.4%10.6%10.9%11.5%
ROE % 18.8%29.4%33.0%27.0%29.7%24.5%25.9%-14.5%11.7%10.9%12.6%
ROCE % --------16.9%15.5%12.4%14.8%

Shareholding Pattern

Insiders
48.86%
Institutions
44.96%
Public Float
87.91%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for METROPOLIS

Google News Sun, 28 Jun 2026

Metropolis Capital Ltd Reduces Stock Holdings in HCA Healthcare, Inc. $HCA - MarketBeat

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOTmtrNzVpSWw0OUd0dHpGaTlVMExjRXNxV0VHMHJDQ3NMa3M2SUk5eTU3V1VuUHJ4SUdMY2xaMk41MFBuXzZCbWdyRjNJSVJfejlpb0VkbHZnTGpuaG5sVzlBOHozekNVMTZWNHFPYm11TVA1RExLMWhhbllvbDdFenZUTFRfSzFEMWlJUD…

Google News Fri, 10 Jul 2026

METROPOLIS Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE84bmV0ZXJTWjBzV2N2d0R3ZE1XWWs2ek9sZFBveEE2Yjd5dWNkVFZENXplUEVkNDJEamtUcmUtX1VaM0lxZUlNTVZOTDRaSUJfVExyc0I4Y2o4bmsyYkVDZUlEY0daczVYZll5ZmRR?oc=5" target="_blank">METROPOLIS Outlook …

Google News Mon, 13 Jul 2026

Top trading ideas: Choice analyst bets on LIC, Bajaj Finserv, Metropolis - Business Standard

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOWVBDWUVvZFY5SllvSmIyWHpvZmVMOXZHNllHOXZic3JJQVVmTnFyZ2FpSGJsME1ZNkY0VmFMSk5JZ1lnbzZMenBNTkw4bnBqQS1YRC1oUG1GNEVBUGNYdVFHT1dzV3hBVDZHNTFJQm5aeFZLa1JKZWQ3RExnQ2NnRElwLVRrbVY1N2Zxen…

Google News ue, 27 Jan 2026

Earnings Tell The Story For Metropolis Healthcare Limited (NSE:METROPOLIS) - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPVEMxTWZIeDRMcG5SS2hiRjFNZ2FXeGNnMzFCdkZaR3RBWHM5OG5YRExhYU5wa1AxdVNsa2N5UWM5R2J0d3Y3V3V4ZEtaNldHeDJ6ZHJvNFpyb0N6RzhUck5Cb3dPZkdraVRXZ2dLUmRHZmpYUGFkNjg1VlZuOVB4blR4a1U5NkRiVHZjWi…

Google News hu, 14 May 2026

Metropolis Healthcare sees strong Q4 performance driven by specialty and preventive testing push - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxQQUZQLUlsUnlnRnAxcExhM2xlNm01cGs1SnV0N2ZBQ1g4bkVsUkJQVUw5WWFOTENUdVp6QTBkd01fOGxfNE9JOUs0MEY4dnlYcFhsS1dBNDE3WUxaU3VVNkJmMUh2YWZYamt0djFQNFZXLXdmd2NHWC0wVmxIalBRSmVpelpZQTk2V3Zic0…

Google News Mon, 06 Jul 2026

Metropolis Healthcare revenue up 16% YoY in Q1FY27 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxOVGRmaTFHOExIT3QwQzVqcHllRmc2dHRic0RZT21YdVpPVlVPQnVXUUNUNHNqRFBqOWY4T2tzOTRPcHZVSEk4MDlud2RWWEd2UGFWRnpMc0MzMm41aEhBdzczeHFJa3V1ZWMxMlNXSVZlZzE4cnpJeG90LVdtOUsxRmF4ZlMtTVVVQ0pyYm…

METROPOLIS — Frequently Asked Questions

What is the current share price of Metropolis Healthcare Limited (METROPOLIS)?

As of 2026-07-15 09:52 IST, Metropolis Healthcare Limited (METROPOLIS) trades at ₹563.40 on NSE. Its 52-week range is ₹420.92 to ₹573.55.

What is the market capitalisation of METROPOLIS?

Metropolis Healthcare Limited (METROPOLIS) has a market capitalisation of ₹11,680.85 Cr on NSE.

What is the P/E ratio of METROPOLIS?

METROPOLIS trades at a trailing price-to-earnings (P/E) ratio of 61.31. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 7.72.

Does METROPOLIS pay a dividend?

Metropolis Healthcare Limited (METROPOLIS) currently offers a dividend yield of 0.35%.

What is the return on equity (ROE) of METROPOLIS?

METROPOLIS has a return on equity (ROE) of 12.56%. Its return on capital employed (ROCE) is 15.73%.

Is METROPOLIS a good stock to buy?

This page provides a data-driven analysis of Metropolis Healthcare Limited (METROPOLIS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space